Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)

Heidemarie Abrahamian1, Peter Hofmann2, Rudolf Prager1, Hermann Toplak313rd Medical Department, General Hospital Hietzing with Neurological Center Rosenhuegel and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Vienna, Austria; 2Department of Psychiatry, University Hospital, Graz,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Heidemarie Abrahamian, Peter Hofmann, Rudolf Prager, Hermann Toplak
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/f688306f8fb04b28972092f9e6e1f8a2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f688306f8fb04b28972092f9e6e1f8a2
record_format	dspace
spelling	oai:doaj.org-article:f688306f8fb04b28972092f9e6e1f8a22021-12-02T07:16:56ZDiabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)1176-63281178-2021https://doaj.org/article/f688306f8fb04b28972092f9e6e1f8a22009-05-01T00:00:00Zhttp://www.dovepress.com/diabetes-mellitus-and-co-morbid-depression-treatment-with-milnacipran--a3105https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Heidemarie Abrahamian1, Peter Hofmann2, Rudolf Prager1, Hermann Toplak313rd Medical Department, General Hospital Hietzing with Neurological Center Rosenhuegel and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Vienna, Austria; 2Department of Psychiatry, University Hospital, Graz, Austria; 3Department of Internal Medicine, University Hospital, Graz, AustriaAbstract: Co-morbid depression is common in patients with diabetes mellitus and has a negative impact on diabetes self-care, adherence to treatment and the development of complications. Effective treatment of depression has been associated with improvement in metabolic parameters. We evaluated the feasibility of a two question screen for co-morbid depression in diabetic patients and studied the effect of the serotonin norepinephrine reuptake inhibitor antidepressant, milnacipran, on metabolic and psychological parameters in 64 type 2 diabetic patients with co-morbid depression. The severity of depression was evaluated using the Beck Depression Inventory (BDI). Patients received milnacipran, and diabetes was treated according to the guidelines of the Austrian Diabetes Association in a 6-month open label study. Metabolic parameters and BDI were measured at baseline and after 1, 3 and 6 months. 46 patients satisfied the criteria for an antidepressant response (reduction of baseline BDI score of at least 50%). Hemoglobin A1c, fasting blood glucose, body mass index, total and LDL-cholesterol and serum triglyceride levels were all significantly decreased in these patients at the end of the study whereas in antidepressant non-responders these parameters were not significantly changed. Diagnosis and treatment of depression is an important factor for the improvement of metabolic control in patients with type 2 diabetes and co-morbid depression. Keywords: depression, diabetes, milnacipran, metabolic control, metformin Heidemarie AbrahamianPeter HofmannRudolf PragerHermann ToplakDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 261-266 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Heidemarie Abrahamian Peter Hofmann Rudolf Prager Hermann Toplak Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
description	Heidemarie Abrahamian1, Peter Hofmann2, Rudolf Prager1, Hermann Toplak313rd Medical Department, General Hospital Hietzing with Neurological Center Rosenhuegel and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Vienna, Austria; 2Department of Psychiatry, University Hospital, Graz, Austria; 3Department of Internal Medicine, University Hospital, Graz, AustriaAbstract: Co-morbid depression is common in patients with diabetes mellitus and has a negative impact on diabetes self-care, adherence to treatment and the development of complications. Effective treatment of depression has been associated with improvement in metabolic parameters. We evaluated the feasibility of a two question screen for co-morbid depression in diabetic patients and studied the effect of the serotonin norepinephrine reuptake inhibitor antidepressant, milnacipran, on metabolic and psychological parameters in 64 type 2 diabetic patients with co-morbid depression. The severity of depression was evaluated using the Beck Depression Inventory (BDI). Patients received milnacipran, and diabetes was treated according to the guidelines of the Austrian Diabetes Association in a 6-month open label study. Metabolic parameters and BDI were measured at baseline and after 1, 3 and 6 months. 46 patients satisfied the criteria for an antidepressant response (reduction of baseline BDI score of at least 50%). Hemoglobin A1c, fasting blood glucose, body mass index, total and LDL-cholesterol and serum triglyceride levels were all significantly decreased in these patients at the end of the study whereas in antidepressant non-responders these parameters were not significantly changed. Diagnosis and treatment of depression is an important factor for the improvement of metabolic control in patients with type 2 diabetes and co-morbid depression. Keywords: depression, diabetes, milnacipran, metabolic control, metformin
format	article
author	Heidemarie Abrahamian Peter Hofmann Rudolf Prager Hermann Toplak
author_facet	Heidemarie Abrahamian Peter Hofmann Rudolf Prager Hermann Toplak
author_sort	Heidemarie Abrahamian
title	Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
title_short	Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
title_full	Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
title_fullStr	Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
title_full_unstemmed	Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)
title_sort	diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the austrian mddm study group)
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/f688306f8fb04b28972092f9e6e1f8a2
work_keys_str_mv	AT heidemarieabrahamian diabetesmellitusandcomorbiddepressiontreatmentwithmilnacipranresultsinsignificantimprovementofbothdiseasesresultsfromtheaustrianmddmstudygroup AT peterhofmann diabetesmellitusandcomorbiddepressiontreatmentwithmilnacipranresultsinsignificantimprovementofbothdiseasesresultsfromtheaustrianmddmstudygroup AT rudolfprager diabetesmellitusandcomorbiddepressiontreatmentwithmilnacipranresultsinsignificantimprovementofbothdiseasesresultsfromtheaustrianmddmstudygroup AT hermanntoplak diabetesmellitusandcomorbiddepressiontreatmentwithmilnacipranresultsinsignificantimprovementofbothdiseasesresultsfromtheaustrianmddmstudygroup
_version_	1718399553587118080

Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)

Ejemplares similares